Journal of Pharmacokinetics & Experimental Therapeutics
Open Access

Pharmacokinetics; Drug design; Early drug discovery; Metabolism, Lead compounds; Drug development; High-throughput screening; Drug optimization

Introduction

The field of drug design and development has seen significant advancements in recent decades, with pharmacokinetics (PK) playing an increasingly important role in the identification and optimization of drug candidates. Pharmacokinetics refers to the study of the absorption, distribution, metabolism, and excretion (ADME) of compounds in the body, which directly impacts their efficacy and safety profiles. Traditionally, PK considerations were incorporated at later stages of the drug development process [1]. However, with the growing complexity of modern therapeutics and the pressure to reduce the high attrition rates of drug candidates, integrating PK principles early in drug design has become a strategic necessity. Early evaluation of PK properties can lead to more informed decisions during lead optimization, reduce the likelihood of late-stage failures, and streamline the development process [2]. This introduction delves into the importance of early PK integration, the challenges involved, and the promising applications of modern techniques to improve PK predictions, ultimately fostering the creation of better-targeted, safer drugs.

Discussion

The integration of pharmacokinetics (PK) into the early stages of drug design has become an essential practice in modern drug discovery and development. One of the primary reasons for this shift is the increasing recognition that ADME (Absorption, Distribution, Metabolism, and Excretion) properties directly affect a drug’s efficacy, safety, and overall clinical success [3]. By evaluating PK data early on, researchers can optimize lead compounds more efficiently, focusing on candidates that will perform better in vivo and have a higher likelihood of clinical success. A major challenge in incorporating PK studies in the early phases of drug design is the need for accurate predictions of human pharmacokinetics from preclinical animal models or in vitro assays [4]. The translation from animal models to human systems often presents difficulties due to species differences in metabolism and drug distribution. However, advancements in in silico modeling have provided more robust predictive tools, enabling researchers to simulate human PK data based on preclinical findings. Computational models now allow for more accurate predictions of how drugs will behave in humans, potentially reducing the number of animal studies and enhancing the early drug development process [5]. Another key challenge is the complexity of human metabolism and the variability among individuals. Variations in liver enzyme activity, genetic differences in transporter proteins, and other factors can all influence how a drug is processed in the body [6, 7]. Although the inclusion of pharmacogenomics and population-based studies has helped mitigate these issues, it remains a difficult aspect of early PK integration. There is also the need for high-throughput screening techniques that can rapidly assess ADME properties across a broad range of compounds. This allows for the identification of compounds with the best overall pharmacokinetic profiles early in the discovery process, reducing costly late-stage failures [8, 9]. Incorporating PK data into the decision-making process early in drug development can also guide optimization strategies. For example, modifying a compound’s chemical structure to enhance absorption or improve metabolic stability can be done much earlier, saving time and resources [10]. Furthermore, early integration of PK can reduce risks associated with adverse drug reactions, as compounds with poor PK profiles are identified and discarded early, thus preventing potential safety issues in later clinical trials.

Conclusion

Incorporating pharmacokinetics early in the drug design and development process is no longer just a recommendation but a necessity. The ability to predict and optimize ADME properties early on enhances the chances of success in clinical trials, reduces development costs, and increases the overall safety and efficacy of drugs. Despite the challenges involved such as the complexity of human metabolism, interspecies differences, and the need for advanced predictive models the field has made considerable progress in overcoming these hurdles. The use of in silico modeling, high-throughput screening, and other innovative technologies provides promising solutions for integrating PK data into early drug discovery stages. Ultimately, the integration of pharmacokinetics into early drug design is a critical strategy for developing safe, effective, and commercially viable therapeutic agents. As research progresses, further advancements in predictive modeling, personalized medicine, and PK study techniques will likely continue to enhance the precision and efficiency of drug development, leading to more successful therapeutic outcomes.

Acknowledgement

None

Conflict of Interest

None

References

1. Zhang HF, Li ZH, Liu JY, Liu TT, Wang P, et al. (2016) Correlation of cytochrome P450 oxidoreductase expression with the expression of 10 isoforms of cytochrome P450 in human liver. Drug Metab Dispos 44:1193-1200.

   Indexed at, Google Scholar, Crossref

2. Puymirat E, Lamhaut L, Bonnet N, Aissaoui N, Henry P, et al. (2016) Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French registry of acute ST-elevation and non-ST-elevation myocardial infarction) programmm. Eur Heart J 37:1063-1071.

   Indexed at, Google Scholar, Crossref

3. Alam P , Chaturvedi SK, Siddiqi MK, Rajpoot RK, Ajmal MR, et al. (2016) Vitamin k3 inhibits protein aggregation: implication in the treatment of amyloid diseases. Sci Rep 6:26759.

   Indexed at, Google Scholar, Crossref

4. Mazerska Z, Mróz A, Pawlowska M, Augustin E (2016) The role of glucuronidation in drug resistance. Pharmacol Ther 159:35-55.

   Indexed at, Google Scholar, Crossref

5. Qi C, Fu J, Zhao H, Xing H, Dong D, et al. (2019) Identification of UGTs and BCRP as potential pharmacokinetic determinants of the natural flavonoid alpinetin. Xenobiotica 49:276-283.

   Indexed at, Google Scholar, Crossref

6. Pettersson Bergstrand M, Richter LH, Maurer HH, Wagmann L, Meyer MR, et al. (2019) In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases. Drug Test Anal 11:45-50.

   Indexed at, Google Scholar, Crossref

7. Chen X, Zhang Q, Cheng Q, Ding F (2009) Protective effect of salidroside against H2O2-induced cell apoptosis in primary culture of rat hippocampal neurons. Mol Cell Biochem 332:85-93.

   Indexed at, Google Scholar, Crossref

8. Fountain NB, Krauss G, Isojarvi J, Dilley D, Doty D, et al. (2013) Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures. Epilepsia 54:58-65.

   Indexed at, Google Scholar, Crossref

9. Cawello W, Boekens H, Bonn R (2012) Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration. Eur J Drug Metab Pharmacokinet 37:241-8.

   Indexed at, Google Scholar, Crossref

10. Chen W, Chan Y, Wan W, Li Y, Zhang C, et al. (2018) Aβ1-42 induces cell damage via RAGE-dependent endoplasmic reticulum stress in bEnd 3 cells. Exp Cell Res 362:83-89.

    Indexed at, Google Scholar, Crossref